Pearl Diagnostics develops in vitro diagnostic assays that detect microbial extracellular vesicles in urine, providing an early indicator of lung infections. This technology enables clinicians to identify and prevent lung infections more effectively, improving patient outcomes.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for lung infections often rely on invasive procedures or late-stage detection, hindering early intervention and potentially leading to poorer patient outcomes. Traditional methods may also lack the specificity needed to differentiate between various types of infections, complicating treatment decisions.
Solution
Pearl Diagnostics offers in vitro diagnostic assays designed to detect microbial extracellular vesicles (EVs) in urine, providing an early indication of lung infections. By identifying these EVs, the assays enable clinicians to detect infections at an earlier stage compared to traditional methods. This early detection facilitates timely intervention and potentially improves patient outcomes by allowing for more targeted and effective treatment strategies. The technology aims to provide a non-invasive and more sensitive approach to lung infection diagnosis.
Target Audience
The primary target audience includes clinicians and healthcare providers involved in the diagnosis and management of lung infections.
Features
- Detects microbial extracellular vesicles (EVs) in urine samples.
- Provides an early indication of lung infections.
- Offers a non-invasive diagnostic approach.
- Enables timely intervention and potentially improves patient outcomes.
- Designed for in vitro diagnostic use.